8-K: MAIA Biotechnology Presents Promising Phase 2 Trial Data for THIO in Advanced Lung Cancer at ASCO 2024

MAIA Biotechnology released updated efficacy and safety data from its Phase 2 THIO-101 clinical trial, showing promising results for THIO in combination with cemiplimab for advanced non-small cell lung cancer patients.

Summary

• MAIA Biotechnology presented data from its Phase 2 THIO-101 clinical trial at the ASCO 2024 Annual Meeting.
• The trial evaluated THIO, a telomere-targeting agent, in combination with the immune checkpoint inhibitor cemiplimab for patients with advanced non-small cell lung cancer (NSCLC) who had failed two or more prior lines of therapy.
• The study enrolled 79 patients and explored different doses of THIO (60mg, 180mg, and 360mg) followed by cemiplimab.
• The trial completed enrollment in February 2024, and the data cutoff was April 30, 2024.
• The 180mg dose of THIO was selected as the best dose in November 2023 due to its superior safety and efficacy profile.
• In the third-line setting, the combination of THIO and cemiplimab showed a Disease Control Rate (DCR) of 85%, compared to 25-35% for standard chemotherapy.
• The Overall Response Rate (ORR) in the third-line setting with the 180mg dose was 38%, compared to 6-10% for standard chemotherapy.
• Median Progression-Free Survival (PFS) in the third-line setting with the 180mg dose was 5.5 months, and the Overall Survival (OS) rate at 6 months was 75%.
• The median survival follow-up time is currently 9.1 months for the third-line setting.
• The treatment was generally well-tolerated, with most adverse events being Grade 1 or 2 in severity.
• Telomere dysfunction induced foci (TIF) analysis demonstrated the intended on-target mechanism of action of THIO.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results, particularly in the third-line setting, with a favorable safety profile. The data suggests a potential breakthrough in a difficult-to-treat patient population, which is likely to be viewed positively by investors.

Positives

• The combination of THIO and cemiplimab shows promising activity in a heavily pre-treated NSCLC patient population.
• The 180mg dose of THIO demonstrated a favorable safety profile with no reported Grade 4 or 5 adverse events.
• The 38% ORR in the third-line setting with the 180mg dose is significantly higher than the 6-10% seen with standard chemotherapy.
• The 85% DCR in the third-line setting is a substantial improvement over the 25-35% seen with standard chemotherapy.
• The median PFS of 5.5 months and 75% OS rate at 6 months in the third-line setting are encouraging.
• The treatment has the potential to be given for longer, which usually translates into longer survival.
• The on-target mechanism of action of THIO was confirmed by TIF analysis.

Negatives

• A Grade 4 liver function test (LFT) elevation was reported in one patient receiving the 360mg dose, leading to a pause in enrollment for that arm.
• Some patients experienced Grade 3 adverse events, including elevated liver enzymes.
• Nausea was reported in 11.4% of patients overall, although only 2.4% at the 180mg dose.
• Decreased appetite was reported in 5.1% of patients overall, although only 2.4% at the 180mg dose.

Risks

• The study is still ongoing, and the data is subject to change.
• The long-term efficacy and safety of the treatment need to be further evaluated.
• The potential for serious adverse events, although low, still exists.
• The results are based on a relatively small sample size, particularly in the third-line setting with the 180mg dose (n=8).

Future Outlook

An expansion cohort is planned based on the data from Part B of the study, with a target enrollment of 100 patients.

Industry Context

The results are significant as they address the unmet need for effective treatments in advanced NSCLC patients who have progressed after prior lines of therapy, including immune checkpoint inhibitors. The data suggests that THIO, a novel telomere-targeting agent, may offer a new approach to overcoming resistance to immunotherapy in this patient population.

Comparison to Industry Standards

• The reported Overall Response Rate (ORR) of 38% in the third-line setting with the 180mg dose of THIO is significantly higher than the 6-10% typically observed with standard chemotherapy in similar patient populations. For example, docetaxel, a common chemotherapy used in this setting, has shown ORRs in the single digits.
• The Disease Control Rate (DCR) of 85% with THIO is also substantially better than the 25-35% seen with chemotherapy. This suggests a greater proportion of patients are experiencing some benefit from the treatment.
• The median Progression-Free Survival (PFS) of 5.5 months in the third-line setting with the 180mg dose is also encouraging when compared to historical data for chemotherapy in this setting, which often shows PFS of only a few months.
• While direct comparisons are difficult due to differences in study design and patient populations, the results suggest that THIO may offer a more effective treatment option than current standards of care for heavily pre-treated NSCLC patients. Companies like AstraZeneca with Tagrisso and Merck with Keytruda have shown success in earlier lines of treatment, but options are limited for patients who progress after these therapies.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical trial results.
• Patients with advanced NSCLC may benefit from a new treatment option.
• The medical community will be interested in the potential of THIO as a telomere-targeting agent.
• The company's employees may be motivated by the positive progress of the clinical trial.

Next Steps

• An expansion cohort is planned with a target enrollment of 100 patients.
• Further analysis of the data will be conducted.
• The company will continue to monitor the long-term efficacy and safety of the treatment.

Key Dates

Keywords

NSCLC, THIO, cemiplimab, lung cancer, telomere targeting, immunotherapy, clinical trial, Phase 2, ASCO, cancer treatment